Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 40.34B P/E 59.23 EPS this Y 7.80% Ern Qtrly Grth 14.10%
Income 681.8M Forward P/E 12.74 EPS next Y 6.20% 50D Avg Chg -
Sales 6.26B PEG 1.63 EPS past 5Y 17.70% 200D Avg Chg 10.00%
Dividend N/A Price/Book 3.25 EPS next 5Y 8.49% 52W High Chg -3.00%
Recommedations 2.70 Quick Ratio 3.47 Shares Outstanding 221.02M 52W Low Chg 83.00%
Insider Own 0.27% ROA 10.08% Shares Float 220.65M Beta 1.26
Inst Own 88.02% ROE 4.43% Shares Shorted/Prior -/- Price 182.50
Gross Margin 90.94% Profit Margin 10.89% Avg. Volume 4,222,993 Target Price 177.36
Oper. Margin 47.41% Earnings Date Oct 27 Volume 3 Change 0.00%
About Alexion Pharmaceuticals, Inc.

Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq for patients with hypophosphatasia; Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency; and Andexxa, a reversal agent for patients treated with rivaroxaban or apixaban. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG, NMOSD, ALS, COVID-19, and HSCT-TMA; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1820 that is in Phase I clinical trial, a therapeutic antagonist of properdin; and ALXN1720, which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 that is in Phase III clinical trials for the treatment of Wilson disease; ALXN1830, which are in Phase I clinical trials for neonatal Fc receptor; ALXN2040 and ALXN2050 to treat diseases associated with dysregulation of the complement alternative pathway; ALXN1850, an enzyme replacement therapy; ALXN2060 for treating transthyretin amyloidosis; and ALXN2075 for treatment of relapsed/refractory chronic lymphocytic leukemia. The company serves distributors, pharmacies, hospital, hospital buying groups, and other healthcare providers in the United States and internationally. The company was incorporated in 1992 and is based in Boston, Massachusetts with an additional office in Switzerland. As of July 21, 2021, Alexion Pharmaceuticals, Inc. operates as a subsidiary of AstraZeneca PLC.

ALXN Chatroom

User Image 11thestate Posted - 1 month ago

$ALXN is accepting claims for a $125M settlement it is paying to investors over illegal sales strategies. Even if the deadline has passed, if you bought between January 30, 2014, and May 26, 2017, you can still file for payment here: https://11thestate.com/cases/alexion-shareholder-settlement

User Image LauriceGeel Posted - 1 month ago

$ALXN Alexion Pharmaceuticals continues to be a leader in rare disease treatments, offering strong growth potential in biotech. A solid healthcare investment. Check out my website, link in bio.

User Image SparkyReturns Posted - 08/22/24

$TAK Check out XERS for another biotech investing idea. Their high-concentration Sub-Q delivery tech can be used with MANY drugs currently being delivered by IV by your company, especially MAbs. XERS already has collabs with big pharma REGN, AMGN, and Beta Bionics. AMGN even ditched HALO recently to go with XERS delivery system instead for Tepezza because higher concentrations and no need for refrigeration. Why am I so optimistic? 1. Stable and growing revenue base of 3 products. 2. SubQ Levo (XP-8121 thyroid treatment) will solve administration issues for people with gastro issues/pills, $2-3B TAM. XERS has hinted about bringing on a partner to monetize value. 3. Will hear soon on collabs with Amgen, Regeneron, and Beta Bionics and will learn soon what the terms are of their upfront payments and milestone payments. 4. Tutes have been quietly loading up, highest institutional ownership ever. How do you like the chart?! Cheers! $DSNKY $ILMN $ALXN $SGEN

User Image Eliza1 Posted - 2 months ago

$AGRI look at $APDN .31 to 2.40...$CING $GOVC $ALXN making incredible moves. This is the time for the company to put out a good PR and get this oversold stock moving!

User Image 11thestate Posted - 2 months ago

$ALXN agreed to settle a $125M with shareholders to end claims that the $ALXN caused a double-digit plunge in stock price after its allegedly illegal sales strategy came to light. And even if you missed the deadline, you can still file a late claim: https://11thestate.com/cases/alexion-shareholder-settlement FAQ for the settlement: 1. Do you need to sell/lose my shares to get this settlement? - No, if you have purchased during the class period, you are eligible. 2. How much money do I get per share? - The average sum is $0.76 per share, but usually, only 25% of all shareholders claim it, so you can get 4x more than this. 3. Who can claim this settlement? - Anyone who purchased $ALXN at any time during the period from and including January 30, 2014, through and including May 26, 2017. 4. How long does the payout process take? - The entire process usually takes 4 to 9 months after the claim deadline. But the exact timing depends on the court and settlement administration. 5. Can I claim even if I missed the deadline? - Yes. It is still possible to file a late claim. The court will decide whether to accept late claims or not. To file a late claim: https://11thestate.com/cases/alexion-shareholder-settlement

User Image 11thestate Posted - 2 months ago

$ALXN agreed to settle a $125M with shareholders to end claims that the $ALXN caused a double-digit plunge in stock price after its allegedly illegal sales strategy came to light. Even if you missed the deadline, you can still file a late claim: https://11thestate.com/cases/alexion-shareholder-settlement

User Image 11thestate Posted - 06/25/24

$ALXN will pay $125M to settle claims with shareholders over allegedly illegal sales strategies that caused a double-digit plunge in stock price. The claim deadline is already passed but you can file a late claim: https://11thestate.com/cases/alexion-shareholder-settlement

User Image TigerZen Posted - 5 months ago

$AKTX I am starting to think $ALXN most likely bought the rights to Nomacopan for HSCT-TMA therapy as it has a PRV voucher attached to it ($100M value) which would give the combined Peak BIO Akari company immediate cash that they need. This is based off an email I sent to Marc Dunoyer (Alexion CEO) and him relaying interest in Akari's nomacopan in a followup email which ultimately connected with Rachelle (Akari CEO).

User Image ca_rott1487 Posted - 6 months ago

$ALXN agreed to settle a $125M with shareholders to end claims that the company caused a double-digit plunge in stock price after its allegedly illegal sales strategy came to light. The deadline has passed but you can file for a late claim:https://11thestate.com/cases/alexion-shareholder-settlement

User Image fin_researcher Posted - 9 months ago

ðŸŽŊA Manhattan judge gave a former $ALXN executive eight months of #housearrest for sharing confidential information about the company's $1.4B #purchase. https://11thestate.com/cases/alexion-shareholder-settlement

User Image STCKPRO Posted - 12/22/23

$ALXN NEW ARTICLE : Doubling Down On Gain Therapeutics https://www.stck.pro/news/ALXN/70710340/

User Image Stan_Vick Posted - 10 months ago

ðŸ’ĩ Alexion pays $125 million to shareholders to end claims over illegal sales strategy. ⚠ïļ $ALXN payout claim deadline - December 15, 2023. Don't forget to take your share of settlement! https://11thestate.com/cases/alexion-shareholder-settlement

User Image fin_researcher Posted - 11 months ago

ðŸŽŊ#Lawfirms are seeking around $31M in attorney fees after securing a $125 million #settlement for $ALXN shareholders. https://11thestate.com/cases/alexion-shareholder-settlement

User Image JoeyTreg Posted - 1 year ago

$OMER From $alxn killer (ðŸ˜‚ðŸ‘ŒðŸ―) to Penny Stock 14 years of leadership from the Demopolous Douchebags!!! a pair of braindead idiots or full fledged scam artist? tell us what you think $GRTS

User Image JoeyTreg Posted - 1 year ago

$OMER bulls remember when dr scam said he felt bad for $ALXN ? because they only had Soliris? 😂😂😂😂 he said his goal was to be the biggest bio out of the northwest?! well, he was partially right hes the biggest bioSCAM out of the entire PLANET!!! $xbi 😂😂😂😂😂😂ðŸĪŠðŸĪŠðŸĪŠðŸĪŠ

User Image fin_researcher Posted - 1 year ago

$ALXN Alexion has reached a $125M million settlement with former shareholders to resolve the misleading lawsuit. If you have traded $ALXN you can claim your part of the settlement here: https://11thestate.com/cases/alexion-shareholder-settlement

User Image Stan_Vick Posted - 1 year ago

✅ Alexion settles a $125 million with investors to end claims that the $ALXN caused a double-digit plunge in stock price after its allegedly illegal sales strategy came to light. ⚠ïļ Payout claim deadline - December 15, 2023! https://11thestate.com/cases/alexion-shareholder-settlement

User Image fin_researcher Posted - 1 year ago

$ALXN Alexion agreed to pay $125M to its former shareholders to end claims that $ALXN caused a double-digit plunge in stock price after its allegedly illegal sales strategy came to light. If you have traded $ALXN you can claim your part of the settlement here: 11thestate.com/cases/alexion-shareholder-settlement

User Image WarnedUBoutStoney Posted - 1 year ago

$ALXN Lol so even here, at the end of all things, Alexion is still a fucking scumbag company.

User Image KobyHiggins Posted - 1 year ago

$YYAI $ALXN $AABB Why are you paying for a trading room? We are opening our trading chat-room to the public'.🚀 https://amazing-stocks-market-today.blogspot.com/2023/09/stock-futures-hold-on-to-slender-gain.html

Analyst Ratings
SVB Leerink Market Perform Mar 23, 21
SVB Leerink Outperform Feb 5, 21
Raymond James Market Perform Jan 8, 21
Truist Securities Hold Dec 16, 20
Citigroup Neutral Dec 15, 20
Credit Suisse Neutral Dec 14, 20
BMO Capital Market Perform Dec 14, 20
Baird Neutral Dec 14, 20
SVB Leerink Outperform Dec 14, 20